Estimated read time: 4-5 minutes
Screening for Alzheimer’s Disease: A Breakthrough Blood Test
ATLANTA — A new study suggests that a blood test, capable of screening for Alzheimer’s disease before symptoms appear, has shown high accuracy. The study focused on testing blood for a key biomarker of Alzheimer’s called p-tau217, which rises in conjunction with beta amyloid and tau proteins in the brains of Alzheimer’s patients. Current diagnose methods involve brain scans or spinal taps, which can be both costly and inaccessible.
The study, published in JAMA Neurology, found that the blood test was as accurate as cerebrospinal fluid tests and brain scans in detecting Alzheimer’s disease pathology in the brain, with accuracy rates of up to 96% for elevated beta amyloid levels and up to 97% for identifying tau levels.
Simple and accurate blood test
The blood test, known as the p-tau217 immunoassay, was studied in a group of 786 participants, with an average age of 66, who underwent brain scans, spinal taps, and blood sample collection. Remarkably, the blood test produced comparable results and accuracies in identifying abnormal beta amyloid and tau, as the more invasive brain scans or spinal taps. Only around 20% of the test group had blood results that were less definitive and required further testing.
“This significant reduction in the need for costly and high-demand examinations brings us closer to blood tests becoming the standard diagnostic procedure in assessing Alzheimer’s disease risk for most individuals,” highlighted Nicholas Ashton, neurochemistry professor at the University of Gothenburg and lead author of the study.
It is crucial to note that while the blood test boasts high accuracy in detecting Alzheimer’s disease characteristics in the brain, individuals with these test results may not necessarily develop the disease. Additionally, the blood test exclusively detects Alzheimer’s disease, making it unable to identify other potential causes of cognitive impairment, such as vascular dementia or Lewy body dementia.
Early intervention and cognitive symptom monitoring
Early diagnosis of Alzheimer’s disease is vital for effective intervention, and this blood test holds immense promise in that regard. Dr. Richard Isaacson, director of research at the Institute for Neurodegenerative Diseases in Florida, suggests administering the test to individuals before they start experiencing cognitive symptoms to better monitor Alzheimer’s progression and gauge the effectiveness of various therapies and lifestyle changes in managing the disease, drawing parallels to routine blood tests for cholesterol in heart disease prevention.
Alzheimer’s disease, the most common type of dementia, affects memory and cognitive functions. While memory problems are often the first indicators of the disease, including losing track of dates and misplacing items, a definitive diagnosis is essential for targeted care.
Approaching a New Era in Alzheimer’s Diagnosis
Scientists behind the groundbreaking study expressing optimism testify to the blood test’s success in accurately identifying Alzheimer’s disease pathology in the brain. With blood tests potentially replacing more invasive procedures and serving as a cost-effective and accessible diagnostic tool, experts anticipate a significant shift in the diagnosis and management of Alzheimer’s disease.
Most Recent Health Stories
More Stories You May Be Interested In
